Senomyx Inc. (SNMX) said that PepsiCo Inc. has exercised its option to extend the companies’ collaborative agreement related to Senomyx’s sweet-taste technology for an additional two years, through August 2016. PepsiCo will continue to have exclusive worldwide rights to the Senomyx sweet flavor ingredients developed under the collaboration for use in non-alcoholic beverage categories. As per the agreement, Senomyx will be entitled to committed research funding payments over the additional two-year period.
Senomyx Inc. (NGM : SNMX), Specialty Chemicals stock ended the day at $8.39, which soared $+0.56 (or +7.15%) and registered an intraday range of $7.85 and $8.44. With 1042262 of its shares exchanged hands during the day versus its average volume of 731012, market capitalization of Senomyx Inc. moved to 356.7 million. The float was recorded 35.58 million compared to 42.52 million outstanding shares.
Seattle Genetics Inc. (SGEN) announced data from several collaborator antibody-drug conjugate (ADC) programs presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting. Seattle Genetics and its collaborators, including Genentech, AbbVie and Progenics, have nine data presentations at ASCO.
Progenics Pharmaceuticals Inc. (NASDAQ : PGNX), flourished +7.87% (or $+0.27) in last trading session and ended the day on $3.70, after wavering among $3.36 and $3.76. The stock’s 52-week range is $7.45 – $3.10 with -6.33%change compare to 18.08% of S&P 500.
Idera Pharmaceuticals Inc. (IDRA) announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400.
Idera Pharmaceuticals Inc. (NCM : IDRA), burgeoned $+0.35 (or +12.87%) in last regular trading to $3.07, after vacillating among $2.74 and $3.19. The stock’s 52-week range is $6.87 – $0.62 with 344.93%change compare to 18.08% of S&P 500.
Bristol-Myers Squibb Company (BMY) and Celldex Therapeutics Inc. (CLDX) announced they have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a Phase 1/2 study.
The price of Celldex Therapeutics Inc. (NASDAQ : CLDX), burgeoned $+1.70 (or +12.64%) to $15.15 in intraday trading post fluctuating among $13.57 and $15.93. Market capitalization of Celldex Therapeutics Inc. is worth nearly $1.354 billion compare to enterprise value of $1.03 billion. The stock’s 52-week range is as $38.84 – $10.76.